CeQur Secures $120M to Expand Insulin Delivery Innovations

CeQur, a Swiss medical device company, has successfully completed a $120 million financing round, led by VI Partners, aimed at accelerating the commercial growth of its 4-day wearable insulin delivery device, CeQur Simplicity. The investment will fund the scaling of the company's sales and clinical teams to enhance accessibility for patients managing diabetes. CeQur's device is already being used by over 6,000 patients and is gaining traction with its ease of use, enhancing insulin regimen adherence and glycemic control. Additionally, the company has improved pharmacy access, achieving significant coverage through Medicare Part-D and Medicaid programs, with most patients facing a monthly copay under $45. In line with its commercial expansion, CeQur's manufacturing facility completed its qualifications and will begin production in 2025. Vi Partners, known for supporting technological and healthcare innovations, reinforces its commitment by investing in CeQur's mission to transform diabetes care.